Ret Proto-Oncogene antibody (Extracellular, N-Term)

Catalog No. ABIN7886748

The Rabbit Polyclonal anti-Ret Proto-Oncogene antibody is suitable to detect Ret Proto-Oncogene in samples from Human. It has been validated for WB, IHC, IF, FACS, LCI and IC.

Quick Overview for Ret Proto-Oncogene antibody (Extracellular, N-Term) (ABIN7886748)

Target: Ret Proto-Oncogene (RET)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ret Proto-Oncogene antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Live Cell Imaging (LCI), Immunochromatography (IC)

Product Details anti-Ret Proto-Oncogene Antibody

Binding Specificity: AA 541-553, Extracellular, N-Term

Purpose: A Rabbit Polyclonal Antibody to Ret Receptor

Cross-Reactivity: Human, Mouse, Rat

Cross-Reactivity (Details): This antibody will recognize the intact Ret receptor and the cleaved Ret extracellular cell-membrane anchored fragment. It won't recognize the cleaved Ret kinase fragment.

Predicted Reactivity: Mouse - identical, rat - 12,13 amino acid residues identical

Characteristics: Anti-Ret (extracellular) Antibody is directed against an extracellular epitope of human Ret. Anti-Ret (extracellular) Antibody ( (ABIN7043600, ABIN7044783 and ABIN7044784) can be used in western blot, indirect flow cytometry, immunohistochemistry and immunocytochemistry applications and has been designed to recognize Ret from rat, mouse and human samples.

Purification: Affinity purified on immobilized antigen.

Immunogen: CEWRQGDGKGITR, corresponding to amino acid residues 541-553 of human Ret

Isotype: IgG

Application Details

Application Notes:

WB: 1:200

FC: 5 μg per reaction

ICC: 1:25

IHC: 1:50

IP: The optimal concentration should be determined by the user

Comment:

Cited Application: ICC

Negative Control: (ABIN7236725)

Blocking Peptide: (ABIN7236725)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Alternative Name: RET

Background:

Synonyms: Proto-oncogene tyrosine-protein kinase receptor Ret, Proto-oncogene c-Ret, Cadherin family member 12, CDHF12

Description: The RET proto-oncogene on human chromosome 10q11.2, encodes a receptor tyrosine kinase (RTK) activated by members of the glial cell line-derived neurotrophic factor (GDNF) ligand family (GDNF, neurturin, artemin, and persephin) in conjunction with a ligand-specific coreceptor (GFRα1-4)1. RET belongs to the cadherin superfamily, and it has been suggested that the ret gene is the result of a recombination between a gene encoding a tyrosine kinase receptor and a gene encoding an ancestral cadherin at an early stage of evolution2. The extracellular domain of RET comprises, as observed for other tyrosine kinase receptors, a cysteine-rich domain, but also four cadherin-like domains3.RET signaling is crucial for the development of the enteric nervous system. RET also regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. Outside the nervous system, RET is crucial for development of the kidney and plays a key role in spermatogenesis3.RET has attracted considerable clinical interest because of the range of mutations found in diverse conditions that include Hirschsprung disease and a variety of cancers involving the thyroid gland. RET-related cancers with thyroid involvement include sporadic and familial medullary thyroid carcinoma (MTC), multiple endocrine neoplasia 2 (MEN2) syndromes MEN2A and MEN2B, and papillary thyroid carcinoma (PTC)4.

Gene ID: 5979

NCBI Accession: NM_020975

UniProt: P07949

Pathways: RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation